©News Group Newspapers Limited in England No. 679215 Registered office: 1 London Bridge Street, London, SE1 9GF. "The Sun", ...

Vermont has the second lowest state fatality rate in the US (147.9 per 100K; Hawaii 113.5/100K). Mississippi (465.6/100K) and ...

Living People’s Pharmacy | Could a new treatment cure lethal blood cancer? By Joe Graedon, M.S., and Teresa Graedon, Ph.D. The People’s Pharmacy ...

Kylian Mbappe of Real Madrid has been hospitalized with acute gastroenteritis, a significant blow to both the team and the inaugural tournament. The i ...

Blujepa: Most recently, the U.S. Food and Drug Administration (FDA) approved Blujepa (gepotidacin), the first of a new class of drugs for the treatment of uncomplicated urinary tract infections caused ...

FDA Approves Powerful Twice-Yearly Treatment to Prevent HIV Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections By Joseph Walker and ...

But like so many before him, his body ultimately surrendered to both the cancer and the aggressive treatment. That’s why we were so excited to learn about a new clinical trial (Journal of ...

EP: 11. Other Investigational Treatment Options for SMA EP: 12. Insurance Considerations for SMA Therapies EP: 13. Optimizing Multidisciplinary Care Approaches for the Future of SMA Management EP: 14.

Girl, 4, Who Was Nearly Deported Despite Getting Life-Saving Medical Treatment, Has Been Granted Permission to Stay The girl was allowed in the U.S. "for life-saving treatment," her lawyers tell ...

AI Impact Winner: Every Cure Newsweek Illustration Every Cure was founded by Dr. David Fajgenbaum and Dr. Grant Mitchell in 2010, in response to a personal crisis. As a third-year medical student ...

Norovirus GII.17 accounted for < 10% of outbreaks in the US 2022-23 season, but rose to 75% during the 2024-25 season, passing the number of GII.4 outbreaks.

Vaxart, Inc., a biotechnology company focused on oral recombinant pill vaccines, announced it will release topline data from its Phase I trial on norovirus before the market opens on June 11, 2025.